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REVIEW
Clinical development of 1% azithromycin in 
DuraSite®, a topical azalide anti-infective for 
ocular surface therapy
Abstract: Conjunctivitis, or inﬂ  ammation of the conjunctiva, refers to a diverse group of ocular 
surface diseases of viral or bacterial origin that primarily affect the conjunctiva. In developed 
countries, the most common causative bacterial pathogens are Staphylococcus aureus, Hae-
mophilus inﬂ  uenzae, and Streptococcus pneumoniae. Most varieties of conjunctivitis are self-
limiting; however, some cases can be extremely contagious or cause serious complications if 
left unchecked. New ocular antibiotics are needed to keep pace with the increasing incidence of 
bacterial resistance and provide options that decrease the overall treatment burden and encourage 
patient compliance. Azithromycin is a well known systemic anti-infective with broad spectrum 
activity against gram positive-, gram negative-, and atypical bacteria species. Ocular use has 
been limited because its solubility and stability proﬁ  les in aqueous media were not favorable 
for delivery to the eye. An eyedrop of 1% azithromycin in DuraSite® (AzaSite™, InSite Vision, 
Alameda, CA, USA), a bioadhesive ocular drug delivery system, was recently developed and 
evaluated in clinical trials. This formulation is well tolerated, delivers a high concentration of 
azithromycin to the conjunctiva, has a broader eradication proﬁ  le than aqueous azithromycin, 
and can be effectively dosed with 7 drops, a 65% reduction in the amount of drops required by 
the most popular antibiotics currently used for conjunctivitis. 
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Introduction
The main etiologic agents in bacterial conjunctivitis are Haemophilus inﬂ  uenzae, 
Staphylococcus aureus, or Steptococcus pnuemoniae. These infections are often self 
limiting. Antibiotics are used with infectious bacterial conjunctivitis to speed recovery, 
reduce complications, and prevent reinfection. Physicians need choices to overcome 
the limitations of frequent dosing, compliance, and bacterial resistance with current 
antibiotic regimens. This review provides an update on the clinical development of 
1% azithromycin formulated with DuraSite® (Insite Vision, Alameda, CA, USA), an 
innovative ocular delivery system that was used to deliver high bactericidal concentra-
tions of azithromycin to the eye to treat bacterial conjunctivitis.
Unmet patient needs in ocular anti-infective 
therapy
The choice of antibiotic therapy for bacterial conjunctivitis is usually empirical. New 
ocular antibiotics are needed to keep pace with the increasing incidence of bacterial 
resistance and to provide patients with a regimen that decreases their overall treatment 
burden and improves the chances for adherence to the treatment. 
Standard topical vehicles such as eyedrops, ointments, and gels are all highly 
effective for treating ocular surface infections, although eyedrops may be more practi-
cal than ointments for daytime use as ointments may interfere with vision. An ideal 
Mitchell H Friedlaender1
Eugene Protzko2
1Division of Ophthalmology, Scripps 
Research Institute,Refractive Surgery 
Program, Scripps Clinic, La Jolla, 
CA, USA; 2Seidenberg Protzko Eye 
Associates, Havre De Grace, MD, USA
Correspondence: Mitchell H. Friedlaender
Division of Ophthalmology, Scripps Clinic, 
1066 N Torrey Pines Rd, La Jolla, CA, 
92037 USA 
Tel +1 858 554 7996 
Fax +1 858 554 6150
Email friedlaender.mitch@scrippshealth.orgClinical Opthalmology 2007:1(1) 4
Friedlaender and Protzko
topical treatment would have the convenience of a drop but 
the long-term duration of an ointment. 
Antibiotic eyedrops are often used to treat acute infectious 
diseases and speed recovery, reduce sequelae, and prevent 
the spread of pathogens through the community. In addition, 
prophylaxis with topical antibiotics is a prudent and necessary 
step to reduce the risk of infection and improve outcomes 
following ophthalmic surgery or ocular trauma (Batequet 
2001; De Kaspar 2004). Powerful medications such as 0.5% 
moxiﬂ  oxacin (Vigamox®; Alcon, Inc, Fort Worth, TX, USA) 
and 0.3% gatiﬂ  oxacin (Zymar®; Allergan, Inc, Irvine, CA, 
USA) increase the number of potential treatment choices 
available to clinicians. However, in order to sustain critical 
bactericidal concentrations of these drops in the eye, dosing 
requirements range from 3 to 8 drops a day (Table 1) (Aller-
gan Inc. 2004; Alcon Laboratories 2005). For some patients 
this is a treatment burden that makes compliance difﬁ  cult. 
Bacterial coverage is an additional concern and unmet 
need in ophthalmology. Depending on the patient’s history, 
ophthalmologists choose from an array of old and new antibi-
otics for the management of ocular surface infection. Newer 
broad-spectrum antibiotics may be more desirable than some 
of the older, narrower-spectrum drugs. However, even with 
the improved activity of newer generation ﬂ  uoroquinolones, 
surveillance studies and regulatory agencies have reported 
changing trends in the susceptibility of infecting organisms 
to ﬂ  uoroquinolones (Goldstein et al 1999; Venezia et al 2001; 
Ambrose et al 2004). Documentation of methicillin resistance 
has also shown an increase in frequency (Shanmuganathan 
et al 2005). Indiscriminate and incorrect ophthalmic usage of 
these powerful broad-spectrum anti-infectives can promote 
the development of resistance. There is still a great need in 
ophthalmology for broad-spectrum antibiotics that can ﬁ  ll the 
coverage gap created by ﬂ  uoroquinolone-resistant bacteria.
Properties of azithromycin
Azithromycin is a semi-synthetic antibiotic that has been suc-
cessfully used in oral and intravenous dosage forms to treat 
gram positive-, gram negative-, and atypical infections of 
the skin and upper respiratory tract (Figure 1). Azithromycin 
is derived from erythromycin and has been available under 
the trade names Zithromax® in the United States, Western 
Europe, and Japan (Pﬁ  zer, Inc., New York, NY, USA) and 
Sumamed® in Eastern Europe (Pliva, Sarajevo, Bosnia and 
Herzegovina). Compared with the narrower-spectrum macro-
lide erythromycin, azithromycin, an azalide, is characterized 
by improved oral bioavailability, increased tissue penetration 
and persistence, and a longer elimination half-life (Piscitelli 
et al 1992; Girard et al 1993). The pharmacokinetic proper-
ties of azithromycin enable short and simple daily dosage 
regimens that can contribute to greater patient compliance 
(Pﬁ  zer, Inc. 2004, 2005).
In vitro studies indicate that azithromycin is highly 
concentrated within polymorphonuclear leucocytes, which 
Table 1 Topical eyedrop regimens used to treat ocular infection
Drug class  Eyedrop  Dosing regimena
    (frequency of 
  administration)
Fluoroquinolone 0.5%  moxiﬂ  oxacin  tid, 7 days
 0.3%  gatiﬂ  oxacin  q2h days 1 and 2b, d qid days 3–7
 0.5%  levoﬂ  oxacin  q2h days 1 and 2b, d q4h days 3–7
 0.3%  oﬂ  oxacin  q2–4h days 1 and 2b, d q4h days 3–7
 0.3%  ciproﬂ  oxacin  q4h 7–14 daysd
Azalide  1.0% azithromycin in DuraSite  bid days 1 and 2 qd days 3–7
Aminoglycoside  0.3% tobramycin  qid days 1–7
  0.3% gentamicin  q4h, 7–10 days
Lipopeptide/dihydrofolate reductase inhibitor  0.1% Trimethoprim sulfate/Polymyxin B sulfate  q3h, 7–10 daysc
  Polymyxin B/neomycin/gramicidin  q3h, 7–10 days
Translation elongation inhibitors  0.5% chloramphenicol  q2h days 1 and 2d q4h days 3–5
  1% fusidic acid  bid days 1–7
Para-aminobenzoic antagonists  10%–20% sodium sulfacetamide  q2h to qid days 1–7d
 4.0%  sulﬁ  soxazole diolamine  qid days 1–7
aAll dosing information from full prescribing information. 
bNot to exceed 8 doses per day. 
cNot to exceed 6 doses per day. 
dDuring waking hours. 
Abbreviations: qd, daily; bid, twice a day; tid, 3 times a day; q2h, every 2 hours; q3h, every 3 hours; q4h, every 4 hours; qid, 4 times a day.Clinical Opthalmology 2007:1(1) 5
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gravitate by chemotactic mechanisms to sites of infection. 
The high intracellular concentration of azithromycin in inﬂ  am-
matory ﬂ  uids of abscesses supports the pharmacodynamic 
properties, which include concentration-dependent killing of 
bacteria and prolonged persistent effects in tissues (Amsden 
2001; Pﬁ  zer, Inc. 2004). 
The primary antibacterial effect of azithromycin differs 
from that of ﬂ  uoroquinolones and involves inhibition of 
protein synthesis and binding of the 50S ribosomal subunit 
(Champney and Miller 2002; Mabe et al 2004). Compared 
with older antibiotics, both azithromycin and the ﬂ  uoroqui-
nolones gatiﬂ  oxacin and moxiﬂ  oxacin are effective against 
gram negative-, gram positive-, and atypical bacteria (Aller-
gan Inc. 2004; Pﬁ  zer, Inc. 2004; Alcon Laboratories 2005). 
Both drug classes have a well known efﬁ  cacy proﬁ  le, but 
systemic use of ﬂ  uoroquinolones is not recommended as 
a ﬁ  rst-line anti-infective in young children (Committee on 
Infectious Diseases 2006). 
A stable, sustained-release 
ophthalmic delivery system 
for azithromycin 
Until recently, ophthalmic uses of azithromycin were limited 
to oral dosing for the treatment of Chlamydia trachomatis 
infections. The safety of three-dose (once per week for 3 
weeks) and single-dose regimens has been demonstrated in 
clinical trials (West 1999). In comparison trials, a single 1-g 
dose of azithromycin was just as effective as a standard 10-day 
treatment with doxycycline (100 mg twice daily) in the treat-
ment of adult inclusion conjunctivitis (Katusic et al 2003). 
Comparative corneal penetration studies in animals 
indicate that aqueous formulations of azithromycin created by 
reconstituting the intravenous dry form of the drug achieved 
higher tissue penetration than the related azalide clarithro-
mycin (Kuehne et al 2004). Reconstituted azithromycin, 
although effective and capable of penetrating the cornea, is 
not suitable as a commercial eyedrop because it lacks long-
term chemical stability and its sterility is not preserved in 
the bottle (Pﬁ  zer, Inc. 2003). These hurdles have recently 
been overcome.
DuraSite® is a drug delivery system that solubilizes 
azithromycin in a sterile aqueous eyedrop. It is a lightly 
cross-linked bioadhesive polymer of polyacrylic acid suit-
able for medical applications that require topical delivery 
and sustained release. The molecular weight of the polymer 
exceeds 1 × 106 Da. The topical formulation of 1% azithro-
mycin in DuraSite (AzaSite™; InSite Vision) is a gel-form-
ing solution that entraps water and the active molecules in 
a bioadhesive matrix. Azithromycin is then held within the 
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Figure 1 Azithromycin, an azalide, is derived from erythromycin but differs chemically in that a methyl substituted nitrogen atom is incorporated into the lactone ring, 
which improves the stability of azithromycin relative to erythromycin.Clinical Opthalmology 2007:1(1) 6
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matrix by continued physical entrapment and reversible ionic 
interaction. In eyedrop formulations with DuraSite, drug 
delivery can be sustained, with release from the matrix tak-
ing place over a period of up to 6 hours (Keller et al 1993; 
Harper et al 1995). 
Azithromycin in DuraSite is preserved with benzal-
konium chloride. The formulation is sterile and stable 
for 9–12 months at room temperature. Initial pharmaco-
kinetic modeling studies of the conjunctival concentra-
tions achieved with a regimen of once-a-day dosing for 5 
days indicated that peak concentrations of 150–200 μg/g 
and trough concentrations of 40 μg/g could be sustained 
during a 24-hour period (Figure 2). These concentrations 
obtained from once-a-day dosing are several fold higher 
than the minimum inhibitory concentrations (MICs) 
needed to fight most ocular surface infections. This is of 
clinical value for patients who are poorly compliant with 
multi-dose eyedrop regimens. Even with these trough 
concentrations, a therapeutic level of azithromycin can 
be maintained throughout the night with once-a-day 
dosing.
Clinical trials of 1% azithromycin 
in DuraSite
Evaluation of the safety and efﬁ  cacy of 1% azithromycin 
in DuraSite was recently completed in a controlled phase 3 
clinical trial for bacterial conjunctivitis. Patients aged 1–96 
years were enrolled in the trial. Clinical and bacteriologic con-
ﬁ  rmation of infection was obtained for the worst affected eye 
at study entry and exit. In most cases, only one eye was treated, 
but the fellow eye could be treated if the infection spread. Two 
masked trials were run simultaneously in which the efﬁ  cacy and 
safety of a 5-day regimen of 1% azithromycin in DuraSite was 
compared with a 5-day regimen of 0.3% tobramycin eyedrops 
or vehicle, dosed 4 times per day.
Subjects in both treatment groups received 20 drops of 
masked study medication. Those who completed the azithro-
mycin arm of the trial received a combination of active drug 
Figure 2 Modeled bioavailability of azithromycin from 1% azithromycin in DuraSite.
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and vehicle-only drops. A loading dose of the active azithro-
mycin eyedrop was administered twice a day on days 1 and 2 
and once a day on days 3 through 5. Clinical resolution was 
deﬁ  ned as the absence of clinical signs and symptoms of bacte-
rial conjunctivitis, speciﬁ  cally conjunctival discharge, bulbar 
conjunctival injection, and palpebral conjunctival injection at 
study exit (visit 3, day 6). At the test-of-cure visit on day 6, 
the efﬁ  cacy data demonstrated that the clinical resolution 
rates of 1% azithromycin in DuraSite were superior to ve-
hicle (63.1% vs 49.7%; p = 0.030 by Fisher exact test) and 
equivalent to 0.3% tobramycin (79.9% vs 78.3%; p = 0.783). 
The most frequently observed ocular adverse events seen in 
1% to 3% of the overall study population were eye irritation, 
conjunctival hyperemia, and worsening conjunctivitis usually 
seen as transfer of infection to the fellow eye during treatment 
(Table 2) (Abelson et al 2006a, b). Upon analysis of tolerability, 
azithromycin in DuraSite was found to be just as comfortable 
as tobramycin or vehicle.
Bacterial eradication was demonstrated as the absence of 
suprathreshold levels of new pathogens in cultures taken at 
study exit. Suprathreshold levels of bacteria were deﬁ  ned as 
levels that could be detected in cultures. The results of the 
exit visit cultures were compared with those obtained at the 
baseline visit. Bacterial eradication with 1% azithromycin in 
DuraSite was just as robust as with 0.3% tobramycin (88.1% 
vs 94.3%, p = 0.073). The most frequently observed bacteria 
upon study entry were S. aureus, S. pneumoniae, and H. 
inﬂ  uenzae. The minimum inhibitory concentrations against 
these bacteria ranged from 0.12 to >1024 μg/mL (Table 3). 
Overall, the clinical resolution rate for these three most com-
mon bacteria was 82%. 
More importantly, the data showed that the antibacte-
rial spectrum of azithromycin in DuraSite included several 
species that were resistant to azithromycin. Resistance was 
deﬁ  ned by the systemic breakpoints as assessed by the Clini-
cal Laboratory and Standards Institute (CLSI). Table 4 lists 
clinical isolates that were resistant when grown in cultures to 
1% azithromycin as determined by the MIC but susceptible 
to 1% azithromycin in DuraSite as evaluated by the absence 
of ocular pathogens at the end of the study. The bacteria were 
isolated from study participants and evaluated for susceptibil-
ity to azithromycin at visit 1 (day 1). At the point-of-cure visit 
(day 6), the data showed that 1% azithromycin in DuraSite 
eradicated 21 of 29 resistant bacterial species (72.4%). Both 
gram positive and gram negative species were eradicated. 
This result suggests that the CLSI systemic breakpoints may 
not be a fair representation of antibiotic activity with topical 
dosing and that the antibiotic effect of azithromycin may have 
been enhanced by the formulation of the azalide in DuraSite.
Infection in children: special issues
In children, the most common cause of conjunctivitis is 
bacterial infection. A 1993 review of cultured pathogenic 
organisms in children found that 80% of conjunctivitis cases 
were bacterial infections, 13% were viral, 2% were allergic, 
and 5% had unidentiﬁ  able causes (Gigliotti et al 1981; Weiss 
et al 1993). According to a review by Lichtenstein and col-
leagues the most common pathogens that cause bacterial 
conjunctivitis in children are H. inﬂ  uenzae, S. pneumoniae, 
and Moraxella catarrhalis (Lichtenstein 2003).
In the US, and less often in the UK, children with bacterial 
conjunctivitis may be excluded from the school setting until 
adequate intervention has been used to prevent contagion 
(American Academy of Pediatrics 2003; Health Protection 
Agency 2006). Sometimes adequate intervention is prob-
lematic with currently available prescription therapies that 
call for 3–8 doses per day because doses may be skipped 
or taken improperly. Currently in the US, ﬂ  uoroquinolone, 
aminoglycoside, or the combination of polymyxin B sulfate 
and trimethoprim sulfate in an ophthalmic solution are the 
most widely prescribed ocular anti-infectives for bacte-
rial conjunctivitis in children (Lichtenstein 2003; Schuman 
2003). Although similar data on the use of ocular solutions 
in Canada are not currently available, the most frequently 
Table 2 Ocular adverse events in phase 3 clinical trials
  Active controlled  Vehicle controlled
 1%      1% 
 azithromycin  0.3%  azithromycin
  in DuraSite  tobramycin  in DuraSite  Vehicle
  (n = 365)  (n = 378)  (n = 333)  (n = 350)
Eye irritation   7 (1.9%)  4 (1.1%)  5 (1.5%)  1 (0.3%)
Conjunctival hyperemia  4 (1.1%)  4 (1.1%)  1 (0.3%)  0 (0%)
Worsening bacterial conjunctivitis  4 (1.1%)  8 (2.1%)  5 (1.5%)  3 (0.9%)Clinical Opthalmology 2007:1(1) 8
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dispensed antimicrobials by retail pharmacies in Canada are 
extended-spectrum penicillins (25%), macrolides (20%), 
tetracyclines (14%), ﬂ  uoroquinolones (12%), and second-
generation cephalosporins (5%) (Public Health Agency of 
Canada 2004). In the United Kingdom, a 5-day regimen of 
chloramphenicol ointment or drops (1 drop every 2 hours on 
days 1 and 2, and 1 drop every 4 hours on days 3 through 
5) is available to treat ocular surface infections. An over-
the-counter formulation of chloramphenicol was recently 
made available for the treatment of bacterial conjunctivitis. 
However, nursing studies have challenged its effective-
ness and safety in children (Harkless 2006). Additionally, 
results from a controlled clinical trial in the UK indicated 
that chloramphenicol was no more effective than placebo 
(Everitt 2006). 
Alternative narrow-spectrum approaches involving 
preparations of fusidic acid that can be dosed twice daily 
for 5–10 days are also being investigated for bacterial con-
junctivitis. Bacteriologic clearance rates of 80% have been 
reported in children of age 2–9 years. The formulations are 
viscous so the drug can stay in contact with the conjunctiva 
longer than traditional drops (Jackson et al 2002; Doughty 
and Dutton 2006). When all options have been considered, 
the dosing regimen for 1% azithromycin in DuraSite appears 
more favorable than the currently available choices in the UK 
and US. In the clinical study, a regimen of 7 drops of 1% 
azithromycin in DuraSite (2 drops on days 1 and 2 and 1 drop 
on days 3 through 5) was found to be equally effective as 20 
drops of tobramycin (65% more drops). Upon approval of 
1% azithromycin in DuraSite by the Food and Drug Admin-
istration, the duration of dosing will most likely be extended 
to 7 days as it has been with all recently approved ocular 
anti-infectives. In either case, this dosing regimen lowers the 
treatment burden on parents and caregivers and increases the 
probability of real-world compliance and successful treat-
Table 3 Clinical and microbiological outcomes
Species MIC  μg/uL (range) N(total) Bacterial  Clinical
     eradication  resolution
Gram (+) strains      
Aerococcus viridans 4 1  100%  100%
CDC coryneform group G  0.008 – >1024  3  100%  100%
Enterococcus faecalis 8  1  100%  100%
Staphylococcus aureus 1  –  >1024  17  82.4%  70.6%
Staphylococcus capitis 1  1  100%  100%
Staphylococcus epidermidis 0.5–256 4  75%  100%
Staphylococcus simulans 1  1  100%  100%
Streptococcus mitis 0.06  4  100%  100%
Streptococcus mitis group 0.06–4  3  100%  100%
Streptococcus oralis 0.12–8  3  100%  100%
Streptococcus pnuemoniae  0.12 – >1024  55  87.3%  85.5%
Streptococcus salivarius 8  1  100%  100%
Viridans streptococcus 8  1  100%  100%
Gram (–) strains      
Enterobacter cloacae 64 1  100%  0%
Haemophilus inﬂ  uenzae 0.5–4 57  93%  89.5%
Klebsiella pneumoniae 16  1  100%  0
Moraxella catarrhalis 0.06  1  100%  100%
Notes: Minimum inhibitory concentration (MIC) values were evaluated at the baseline visit on day 1. Bacterial eradication and clinical resolution were evaluated in the per 
protocol population at the point of cure visit on day 6.
Table 4 Eradication of azithromycin-resistant organisms by 1% 
azithromycin in DuraSite
 Azithromycin-resistant 
  organisms killed, % (n/N)
Resistant organism 
Staphylococcus aureus 50%  (2/4)
Staphylococcus epidermidis 100%  (2/2)
Staphylococcus simulans NAa
Streptococcus mitis 100%  (3/3)
Streptococcus mitis group 100%  (1/1)
Streptococcus oralis 100%  (2/2)
Streptococcus pneumoniae 60%  (9/15)
Streptococcus salivarius 100%  (1/1)
Streptococcus viridans   100% (1/1)
Total 72.4%  (21/29)
aOrganisms without minimum inhibitory concentration result interpretation or 
resistant organism not available.Clinical Opthalmology 2007:1(1) 9
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ment outcomes. Azithromycin in DuraSite ﬁ  lls an unmet 
need in ophthalmology.
Usefulness in ophthalmic practice
Azithromycin provides excellent coverage of the pathogens 
that are the most common cause of bacterial conjunctivitis in 
adults, S. aureus, H. inﬂ  uenzae, and S. pneumoniae (Morrow 
and Abbott 1998), and its combination with the bioadhesive 
properties of DuraSite may enhance its antibiotic effect 
against microbes that were commonly considered resistant 
to azithromycin. 
For example, although other bacteria may be involved, 
Staphylococcus species are prevalent in many patients with 
chronic bacterial conjunctivitis. This type of conjunctivitis 
often develops in association with blepharitis, a common but 
often unrecognized inﬂ  ammatory condition related to bacte-
rial colonization of the eyelid margins. In adults, blepharitis 
often is associated with systemic diseases such as rosacea. 
The work-up of patients with chronic conjunctivitis and 
blepharoconjunctivitis involves culturing the conjunctiva 
and the eyelid margins to identify the predominant bacterial 
pathogen. Treatment includes the establishment of good 
eyelid hygiene, using warm compresses and eyelid margin 
scrubs and the application of appropriate topical antimicro-
bials (eg, erythromycin or sulfacetamide ointment) for 1–2 
weeks (Morrow and Abbott 1998; American Academy of 
Ophthalmology 2003). 
Recurrence of blepharitis in adults is high (American 
Academy of Ophthalmology 2003). Twenty-four-hour cov-
erage with ointments may be difﬁ  cult to achieve since their 
use can cause blurriness, thereby making daytime application 
inconvenient for patients. 
The gel-forming eyedrop of azithromycin in DuraSite 
drop provides the desired long-term residence time in the eye 
and in clinical trials. In the trial, 1% azithromycin in Dur-
aSite eliminated 82% of S. aureus, including some species 
that are considered resistant to azithromycin. Formulations 
of sustained-acting drugs in DuraSite have been evaluated 
before. In these cases as well as with azithromycin, blurri-
ness from the formulation was not a major safety ﬁ  nding 
(Harper et al 1995). Patients with blepharoconjunctivitis 
could beneﬁ  t from the antibiotic coverage of ocular azithro-
mycin in DuraSite. 
Conclusions
There are several compelling reasons why 1% azithromy-
cin in DuraSite will be a welcome addition to the class of 
ophthalmic antibiotics; it offers a simpliﬁ  ed dosing regimen 
that is convenient and effective, the potential for increased 
compliance and successful therapeutic intervention because 
therapy can be completed with 7 drops administered over 
5 days, and high bactericidal levels that can be sustained 
in the eye overnight, and the potential for reduction in the 
development of resistance by effectively killing sensitive 
organisms.
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